Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 2/20 | 0.53 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.51 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | PTGES | O14684 | 1/20 | 0.49 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.49 |
| ▸ | PPARG | P37231 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7916834 | 0.89 | MAOB (0.52) | — | |
| SCHEMBL1856418 | 0.88 | ALDH1A1 (0.56) | GRIK1KMT2AALOX5RAB9A | |
| SCHEMBL1856039 | 0.88 | L3MBTL1 (0.50) | MTNR1AMTNR1BL3MBTL1SIGMAR1HDAC1 | |
| SCHEMBL1861101 | 0.84 | ALDH1A1 (0.53) | GRIK1KMT2AALOX5RAB9A | |
| SCHEMBL3467371 | 0.84 | MMP3 (0.58) | SIGMAR1GRIK1KMT2AALOX5RAB9A | |
| SCHEMBL30724099 | 0.84 | MTNR1A (0.50) | MTNR1AMTNR1BHDAC1HDAC6KMT2A | |
| SCHEMBL10643738 | 0.83 | LDHA (0.54) | KMT2AALOX5PPARG | |
| SCHEMBL1860416 | 0.83 | GRIK1 (0.68) | HDAC1HDAC6GRIK1PTGESALOX5 | |
| SCHEMBL28820181 | 0.82 | MTNR1A (0.57) | MTNR1AMTNR1BSIGMAR1HDAC1HDAC6 | |
| SCHEMBL28020307 | 0.82 | MTNR1A (0.57) | MTNR1AMTNR1BSIGMAR1HDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105544-A1 | CARBOXYLIC DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | CRYSTAX PHARMACEUTICALS, S.L. (ES) | 2011-05-05 | — | — | US | claimed |
| WO-2009080722-A2 | CARBOXYLIC DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | CRYSTAX PHARMACEUTICALS, S.L. (ES) | 2009-07-02 | — | — | WO | claimed |
| US-20110105544-A1 | CARBOXYLIC DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | CRYSTAX PHARMACEUTICALS, S.L. (ES) | 2011-05-05 | — | — | US | disclosed |
| US-20110105544-A1 | CARBOXYLIC DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | CRYSTAX PHARMACEUTICALS, S.L. (ES) | 2011-05-05 | — | — | US | disclosed |
| WO-2009080722-A2 | CARBOXYLIC DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | CRYSTAX PHARMACEUTICALS, S.L. (ES) | 2009-07-02 | — | — | WO | disclosed |
| WO-2009080722-A2 | CARBOXYLIC DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | CRYSTAX PHARMACEUTICALS, S.L. (ES) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105544-A1 | CARBOXYLIC DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | AKR1C3, TPD52L2, HCCS | MTNR1A 515/4885MTNR1B 605/4885L3MBTL1 2630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.